

Amendments to the claims:

This listing of claims will replace the prior version, and listing, of claims in the application:

Listing of Claims:

Claims 1-10 Canceled

Claim 11 (new) A method of treating psoriasis affected area of the skin, scalp or nails comprising the steps of:

a) Orally administering to the psoriasis affected individual a composition comprising boswellic acid and a selenium compound, dispersed in a pharmaceutically acceptable carrier; and b) topically applying to the said affected area a composition of boswellic acid dispersed in a pharmaceutically acceptable carrier.

Claim 12 (new): The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim 1 wherein the orally administered composition contains from about 50 mg to about 500 mg of boswellic acid represented by one or more of the following groups: a) beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as single entities or mixtures. b) Congeners or derivatives of beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as single entities or mixtures.

Claim 13 (new): The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim 1 wherein the orally administered composition contains about 50 micrograms to about 200 micrograms of selenium derived from one or more of the following selenium sources: selenomethionine, Se-methylselenocysteine, derivatives of selenomethionine, derivatives of Se-methylselenocysteine, high selenium yeast.

Claim 14 (new): The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim 1 wherein the topically administered composition contains from about 50 mg to about 400 mg of boswellic acid represented by one or more of the following groups: a) beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as single entities or mixtures, b) Congeners or

derivatives of beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11keto-beta-boswellic acid, as single entities or mixtures.

Claim 15 (new): The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim 1 wherein the orally administered composition contains from about 10mg to about 400 mg of acetyl-11-keto-beta-boswellic acid.

Claim 16 (new): The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim 1 wherein the orally administered composition contains from about 0.001 micrograms to about 100 micrograms of L(+)-Selenomethionine, dispersed in a pharmaceutically acceptable carrier.

Claim 17 (new): The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim 1 wherein the topically administered composition contains from about 10mg to about 400 mg of acetyl-11-keto-beta-boswellic acid dispersed in a pharmaceutically acceptable carrier.

Claim 18 (new): The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim 1 wherein the total daily oral dose of boswellic acid is from about 50 mg to about 2000 mg, administered in a single dose or in a plurality of individual doses.

Claim 19 (new): The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim 1 wherein the total daily oral dose of selenium is from about 0.001 micrograms to about 400 micrograms, administered in a single dose or in a plurality of individual doses.

Claim 20 (new): The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim 1 wherein the total daily topical dose of boswellic acid is from about 10 mg to about 1600 mg, administered in a single dose or in a plurality of individual doses.